| 1357 |
National Cancer Institute |
Html |
en |
Fatigue (PDQ®)–Health Professional Version |
Expert-reviewed information summary about fatigue, a condition marked by extreme tiredness and inability to function because of lack of energy, often seen as a complication of cancer or its treatment. |
| fatigue syndrome | 0.551792 |
| severe fatigue | 0.49185 |
| cancer-related fatigue | 0.710712 |
| Fatigue Coalition | 0.462842 |
| fatigue ratings | 0.435783 |
| fatigue | 0.998693 |
| exhibit peak fatigue | 0.502775 |
| fatigue severity | 0.46154 |
| Cancer Nurs | 0.388926 |
| fatigue outcomes. | 0.43447 |
| evening fatigue | 0.483354 |
| muscle fatigue | 0.440015 |
| chronic fatigue | 0.543247 |
| cancer treatment–related fatigue | 0.605063 |
| breast cancer patients | 0.407613 |
| patients | 0.57543 |
| cancer patients | 0.477381 |
| Fatigue Symptom Inventory | 0.497603 |
| breast cancer survivors | 0.539985 |
| cancer survivors | 0.554969 |
| radiation therapy | 0.80026 |
| Pain Symptom Manage | 0.426561 |
| cancer fatigue | 0.565306 |
| fatigue levels | 0.472762 |
| Healthy fatigue | 0.483034 |
|
| et al. | 0.481346 |
| fatigue scores | 0.45955 |
| study | 0.418279 |
| Oncol Nurs Forum | 0.493357 |
| Brief Fatigue Inventory | 0.449476 |
| persistent fatigue | 0.499021 |
| fatigue trajectory | 0.465086 |
| acute fatigue | 0.483368 |
| morning fatigue | 0.469862 |
| PUBMED Abstract | 0.401763 |
| label chronic fatigue | 0.506385 |
| reduced fatigue | 0.424645 |
| fatigue management focus | 0.514449 |
| Mental fatigue | 0.462612 |
| Abstract | 0.416565 |
| Clin Oncol | 0.445675 |
| breast cancer | 0.789754 |
| fatigue management. | 0.459872 |
| postoperative fatigue | 0.468487 |
| severe fatigue category | 0.447818 |
| Lee Fatigue Scale | 0.483435 |
| chronic fatigue syndrome | 0.508959 |
| cancer | 0.840288 |
| chronic cancer-related fatigue | 0.523182 |
|
CLICK HERE |
| 1444 |
National Cancer Institute |
Html |
en |
Adult Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult acute myeloid leukemia. |
| characteristic genetic abnormalities | 0.39234 |
| Adult Acute Myeloid | 0.42781 |
| acute myelogenous leukemia | 0.488829 |
| acute biphenotypic leukemia | 0.454638 |
| Acute myeloblastic leukemia | 0.474183 |
| acute erythroblastic leukemia | 0.447971 |
| monoblastic leukemia antigens | 0.403407 |
| transient leukemia | 0.398296 |
| Leukemia Group | 0.421425 |
| acute eosinophilic leukemia | 0.464145 |
| acute leukemias | 0.416535 |
| biphenotypic acute leukemia | 0.461147 |
| acute monocytic leukaemia | 0.396733 |
| chronic myeloid leukemia | 0.484726 |
| chronic myelomonocytic leukemia | 0.40262 |
| AML | 0.598074 |
| World Health Organization | 0.418965 |
| Health Organization Classification | 0.417813 |
| acute monocytic leukemia | 0.541741 |
| minimally differentiated AML | 0.404409 |
| acute erythroid leukemias. | 0.391545 |
| acute leukemia patients | 0.46612 |
| blast percentage | 0.399782 |
| myelodysplastic syndromes | 0.404558 |
| et al. | 0.486443 |
|
| lineage acute leukemia | 0.472137 |
| acute megakaryoblastic leukemia | 0.570037 |
| acute biphenotypic leukaemia | 0.396849 |
| internal tandem duplication | 0.391126 |
| Br J Haematol | 0.407064 |
| acute monoblastic leukemia | 0.552455 |
| adult megakaryoblastic leukemia | 0.392499 |
| acute myeloid leukemia | 0.936356 |
| acute myeloid leukaemia | 0.463297 |
| acute myelomonocytic leukemia | 0.509496 |
| genetic abnormalities | 0.393333 |
| acute megakaryocytic leukemia | 0.467082 |
| differential diagnosis | 0.419864 |
| cases | 0.405688 |
| Abstract | 0.458712 |
| pure erythroid leukemia | 0.448165 |
| cytochemical features | 0.408002 |
| acute erythroid leukemia | 0.471063 |
| bone marrow | 0.469209 |
| acute erythroid leukemias | 0.400236 |
| acute promyelocytic leukemia | 0.615165 |
| acute nonlymphocytic leukemia | 0.489262 |
| acute lymphoblastic leukemia | 0.489649 |
| acute leukemia | 0.565771 |
|
CLICK HERE |
| 1539 |
National Cancer Institute |
Html |
en |
Adult Primary Liver Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of adult primary liver cancer. |
| Adult liver cancer | 0.3229 |
| bile duct cancer | 0.289957 |
| cancer spreads | 0.268265 |
| body | 0.335412 |
| healthy liver tissue | 0.301199 |
| PDQ cancer information | 0.323551 |
| clinical trial search | 0.281007 |
| clinical trials | 0.55174 |
| cancer information summary | 0.30136 |
| adult primary liver | 0.896168 |
| clinical trial | 0.389615 |
| liver disease | 0.276306 |
| detailed pictures | 0.294233 |
| healthy donated liver | 0.285489 |
| treatment clinical trial | 0.264079 |
| body radiation therapy | 0.304178 |
| NCI PDQ cancer | 0.273742 |
| malignant tumor cells | 0.27026 |
| Duct Cancer Treatment | 0.289551 |
| radiation therapy | 0.397919 |
| Childhood Liver Cancer | 0.337182 |
| entire liver | 0.272876 |
| general cancer information | 0.265929 |
| treatment | 0.426881 |
| liver injury | 0.286661 |
|
| hepatic portal vein | 0.283724 |
| Clinic Liver Cancer | 0.322316 |
| metastatic liver cancer | 0.323102 |
| nearby healthy tissue | 0.265169 |
| NCI-supported cancer | 0.264234 |
| cancer cells | 0.36535 |
| hepatic artery | 0.317753 |
| primary liver cancer | 0.97153 |
| Cancer Information Service | 0.266321 |
| specific cancer cells | 0.265527 |
| Liver Cancer Treatment | 0.368965 |
| patient | 0.265351 |
| treatment clinical trials | 0.285012 |
| National Cancer Institute | 0.332241 |
| stereotactic body radiation | 0.30319 |
| liver transplant | 0.296023 |
| new treatment | 0.282659 |
| external radiation therapy | 0.294036 |
| blood | 0.29169 |
| PDQ summary | 0.268144 |
| cancer clinical trials | 0.30738 |
| tumor | 0.3047 |
| cancer information summaries | 0.264877 |
| comprehensive cancer information | 0.264661 |
|
CLICK HERE |
| 1571 |
National Cancer Institute |
Html |
en |
Oropharyngeal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of oropharyngeal cancer. |
| clinical trial | 0.317401 |
| treatment | 0.389236 |
| lymph node | 0.268655 |
| radiation therapy | 0.666089 |
|
| cancer | 0.907557 |
| clinical trials | 0.51831 |
| cancer cells | 0.317956 |
|
CLICK HERE |
| 1634 |
National Cancer Institute |
Html |
en |
Hydrazine Sulfate (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of hydrazine sulfate as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| randomized controlled trials | 0.450078 |
| treatment | 0.522727 |
| cancer treatment | 0.475015 |
| cancer prevention | 0.44047 |
| Complementary Therapies Editorial | 0.452982 |
| United States | 0.440744 |
| Drug Administration | 0.454034 |
| Cancer Information Specialist | 0.44699 |
| cancer cells | 0.451523 |
| Cancer Information Service | 0.478296 |
| hydrazine compounds | 0.44033 |
| PDQ cancer information | 0.502287 |
| Cancer Complementary | 0.451114 |
| body weight | 0.443552 |
| hydrazine sulfate treatment | 0.519798 |
| preclinical studies | 0.453016 |
| CAM therapies | 0.439277 |
| treatment clinical trials | 0.44455 |
| National Cancer Institute | 0.557582 |
| studies | 0.47528 |
| clinical trials | 0.59962 |
| colon cancer patients | 0.451298 |
| alternative medicine | 0.474569 |
| conventional treatment | 0.441057 |
|
| cancer information summary | 0.479257 |
| alternative cancer therapies | 0.448575 |
| Federal Trade Commission | 0.442333 |
| National Institutes | 0.438958 |
| clinical trial | 0.445969 |
| lung cancer patients | 0.451382 |
| CAM cancer research | 0.443791 |
| nutritional status | 0.439129 |
| breast cancer prevention | 0.438548 |
| advanced cancer | 0.438703 |
| patients | 0.50459 |
| cancer patients | 0.480463 |
| Cancer Care page | 0.43981 |
| health | 0.440064 |
| hydrazine sulfate | 0.914395 |
| PDQ summary | 0.439248 |
| NCI PDQ cancer | 0.463099 |
| cancer information database | 0.449512 |
| effects | 0.440229 |
| alternative therapies | 0.459489 |
| cancer information summaries | 0.449727 |
| Therapies Editorial Board | 0.445847 |
| randomized clinical trials | 0.444095 |
|
CLICK HERE |
| 1660 |
National Cancer Institute |
Html |
en |
Liver (Hepatocellular) Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for liver (hepatocellular) cancer. |
| PDQ Screening | 0.551346 |
| hepatocellular) cancer: | 0.719756 |
| cancer treatment | 0.490974 |
| cancer screening methods | 0.577774 |
| United States | 0.488028 |
| ongoing clinical trials | 0.569331 |
| routine screening tests | 0.542104 |
| Abnormal screening results | 0.526706 |
| following PDQ summaries | 0.569947 |
| Cancer Information Service | 0.537158 |
| PDQ cancer information | 0.763376 |
| false-negative test result | 0.487695 |
| widely used tumor | 0.492628 |
| common cancer | 0.497307 |
| Prevention Editorial Board | 0.554017 |
| treatment clinical trials | 0.497409 |
| National Cancer Institute | 0.639479 |
| clinical trials | 0.758209 |
| early detection | 0.490925 |
| PDQ documents | 0.509492 |
| test result | 0.528806 |
| cancer information summary | 0.632034 |
| new treatment | 0.500882 |
| breast cancer prevention | 0.517023 |
|
| diagnostic tests | 0.505464 |
| test results | 0.489974 |
| Cancer screening trials | 0.585626 |
| tumor markers | 0.491268 |
| NCI website | 0.503158 |
| false-positive test result | 0.487287 |
| cancer patients | 0.48575 |
| Cancer Care page | 0.521215 |
| PDQ database | 0.515283 |
| latest published information | 0.502276 |
| specific tumor marker | 0.485952 |
| NCI’s PDQ | 0.524006 |
| risk factor | 0.495527 |
| PDQ summary | 0.551372 |
| liver biopsy | 0.551147 |
| cancer symptoms | 0.506472 |
| NCI PDQ cancer | 0.600996 |
| Chinese American men | 0.489845 |
| tests | 0.559642 |
| cancer information summaries | 0.546479 |
| comprehensive cancer information | 0.546147 |
| cancer | 0.936669 |
| liver cancer | 0.793964 |
|
CLICK HERE |
| 1874 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores extragonadales de células germinativas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores extragonadales de células germinativas. |
| germ-cell tumors | 0.383819 |
| metastatic germ | 0.316138 |
| germ-cell tumors with | 0.328427 |
| residual mass | 0.330871 |
| Nichols CR | 0.459486 |
| Greco FA | 0.321626 |
| initial salvage therapy | 0.319174 |
| largo plazo | 0.317683 |
| following systemic chemotherapy | 0.321834 |
| with germ-cell tumors | 0.328027 |
| malignant germ-cell tumors | 0.322658 |
| single-institution experience with | 0.326215 |
| unknown primary site | 0.318402 |
| germ cell tumours | 0.337125 |
| Extragonadal germ | 0.317435 |
| Cell Cancer Collaborative | 0.335481 |
| Hainsworth JD | 0.322365 |
| cell or non-germ | 0.330347 |
| Williams SD | 0.32023 |
| salvage treatment | 0.337434 |
| high-dose chemotherapy | 0.334497 |
| Instituto Nacional | 0.329901 |
| International Germ Cell | 0.371979 |
| Tumores mixtos | 0.340879 |
| Advanced poorly differentiated | 0.316704 |
|
| cell malignancy after | 0.327663 |
| primary mediastinal nonseminomatous | 0.349396 |
| unrecognized germ | 0.316359 |
| patients with | 0.426473 |
| Kramar A | 0.320119 |
| germ cell neoplasms | 0.33799 |
| disseminated germ | 0.332449 |
| Einhorn LH | 0.38746 |
| Germ Cell Consensus | 0.341019 |
| effective chemotherapy regimen | 0.321136 |
| Salvage chemotherapy | 0.319709 |
| germ cell | 0.988418 |
| PDQ Tratamiento | 0.334355 |
| extragonadal nonseminomatous germ | 0.321388 |
| Indiana University | 0.317574 |
| Clin Oncol | 0.830939 |
| as salvage treatment | 0.323614 |
| mediastinal germ-cell tumors | 0.323089 |
| mediastinal nonseminomatous germ | 0.353563 |
| postchemotherapy residual mass | 0.322319 |
| germ cell tumors | 0.75596 |
| Catalano PJ | 0.324048 |
| Oncology Group | 0.318284 |
| germ cell cancer | 0.426267 |
|
CLICK HERE |
| 2117 |
National Cancer Institute |
Html |
es |
Brotes de cáncer |
Hoja informativa que describe lo que es un brote de cáncer, el proceso para notificar e investigar brotes sospechosos y los retos en la investigación de brotes sospechosos. |
| Seguridad Ocupacional | 0.284426 |
| posibles carcinógenos | 0.307688 |
| múltiples tipos | 0.294654 |
| Centro Nacional | 0.429489 |
| Health Consultations. | 0.283346 |
| cabo programas | 0.28293 |
| Sustancias Tóxicas | 0.544168 |
| Public Health Assessments | 0.353028 |
| ambiente causantes | 0.320442 |
|
| Salud Ambiental | 0.29888 |
| Estados Unidos | 0.297229 |
| Medicina Ocupacional | 0.42476 |
| claro exceso | 0.319927 |
| cabo evaluaciones | 0.29639 |
| Cáncer usa datos | 0.931444 |
| contaminante ambiental | 0.520538 |
| contaminante sospechoso | 0.478153 |
|
CLICK HERE |
| 14597 |
National Cancer Institute |
Html |
en |
Common Cancer Myths and Misconceptions |
The latest science-based information concerning some common misconceptions about cancer. Learn the facts to worry less and make good health decisions. |
| cancer treatment | 0.293552 |
| multiple family members | 0.287169 |
| different surgical tools | 0.292574 |
| best studies | 0.351264 |
| wrong ideas | 0.256786 |
| individual cancer patient | 0.352232 |
| Cancer patients | 0.292909 |
| artificial sweeteners | 0.340098 |
| Cancer Vaccines | 0.299159 |
| bladder cancer | 0.291637 |
| good prevention | 0.259057 |
| Cancer Risk | 0.329552 |
| tobacco smoke | 0.287568 |
| environmental factors | 0.290117 |
| Risk Factors | 0.292696 |
| magnetic energy | 0.286101 |
| complementary therapies | 0.281474 |
| person | 0.354916 |
| cancers | 0.347867 |
| Five-year survival rates | 0.302006 |
| common cancer myths | 0.360301 |
| Metastatic Cancer | 0.322576 |
| Annual Report | 0.258223 |
| NCI fact sheet | 0.996571 |
| United States | 0.312478 |
|
| excess weight gain | 0.296228 |
| cancer cells | 0.333742 |
| 5-year survival rate | 0.300282 |
| Helicobacter pylori | 0.298521 |
| personal hair dye | 0.285054 |
| natural result | 0.291706 |
| Hereditary Cancer Syndromes | 0.328419 |
| cell phones | 0.296722 |
| scientific evidence | 0.293613 |
| No. Researchers | 0.257042 |
| needless worry | 0.25947 |
| old theories | 0.256313 |
| transplant-related cancer | 0.304436 |
| NCI fact sheets | 0.326267 |
| Botanicals/Herbal Products section | 0.288672 |
| No. | 0.263456 |
| Breast Cancer | 0.289863 |
| medicine products—including vitamins | 0.287253 |
| latest science-based information | 0.32382 |
| power lines | 0.324548 |
| thyroid cancers | 0.300398 |
| Certain popular ideas | 0.304234 |
| cancer | 0.824886 |
| information | 0.40326 |
|
CLICK HERE |
| 16448 |
National Cancer Institute |
Html |
en |
Identifying Novel Drug Combinations to Overcome Treatment Resistance |
A review of current research identifying and testing drug combination approaches that have the potential to overcome or delay resistance to cancer treatment. |
| cancer treatment | 0.25347 |
| cancer cell lines—a | 0.280999 |
| healthy cells | 0.296062 |
| novel drug combinations | 0.308632 |
| lung cancer | 0.280527 |
| chemotherapy resistance | 0.310051 |
| cancer drug resistance | 0.46496 |
| Kettering Cancer Center | 0.280587 |
| effective drug pairs | 0.26607 |
| clinical trials | 0.313646 |
| epigenetic alterations | 0.2886 |
| original drug | 0.25941 |
| molecular alterations | 0.297668 |
| myeloid cells | 0.309525 |
| ovarian cancer | 0.356692 |
| cisplatin resistance | 0.289204 |
| patients | 0.50622 |
| immune checkpoint inhibitors | 0.342594 |
| single tumor | 0.262236 |
| Nature Reviews Cancer | 0.299509 |
| potential drug combinations | 0.282064 |
| tumor—contain molecular alterations | 0.269672 |
| combination treatment approach | 0.285984 |
| multidrug resistance section | 0.355811 |
| drug resistance | 0.805264 |
|
| cancer drugs | 0.296242 |
| treatment | 0.450602 |
| Cancer Research UK | 0.305072 |
| ABC transporter inhibitors | 0.39367 |
| chemotherapy drugs | 0.281313 |
| breast cancer tumors | 0.293816 |
| cancer cells | 0.926321 |
| cancer cell lines | 0.386565 |
| so-called intrinsic resistance | 0.362006 |
| epigenetic alteration | 0.261391 |
| Dana-Farber Cancer Institute | 0.280545 |
| Dr. Gottesman | 0.323556 |
| DNA methylation | 0.280984 |
| Cancer Research | 0.350827 |
| ABC transporters | 0.47073 |
| Hospital Cancer Center | 0.277242 |
| epigenetic codes—molecular modifications | 0.267446 |
| cancer researchers | 0.266263 |
| inactivating T cells | 0.270905 |
| drugs | 0.323984 |
| ovarian cancer cell | 0.296997 |
| drug combinations | 0.458324 |
| tumor microenvironment | 0.309626 |
| lung cancer cell | 0.275824 |
|
CLICK HERE |